| Size | Price | |
|---|---|---|
| 1mg | ||
| 5mg | ||
| 10mg | ||
| Other Sizes |
ST-193 HCl is a novel and potent arenavirus inhibitor with a broad-spectrum of antiviral activity against Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
| ln Vitro |
At a 1.6 nM IC50, ST-193 suppresses LASV pseudotypes. Although the IC50 values for Junín, Machupo, Guanarito, and Sabiá ranged from 0.2 to 12 nM, ST-193 also suppresses the pseudotypes generated by other arenavirus envelopes, which includes the other four viruses that are frequently linked to hemorrhagic fevers. However, the pseudotyped viruses that contained arenavirus envelopes exhibited no antiviral characteristics. Up to 10 μM of either unrelated G protein from vesicular stomatitis virus or GP from the LASV-related arenavirus lymphocytic choriomeningitis virus [2].
|
|---|---|
| ln Vivo |
The study indicated that ST-193 was well tolerated when delivered intraperitoneally at 25 or 100 mg/kg/day for 14 days. ST-193-treated animals showed fewer indications of disease and enhanced survival compared with the ribavirin or vehicle groups. Body temperature increased in all groups by day 9, but most ST-193-treated animals reverted to normal body temperature by day 19 post-infection. ST-193 therapy caused a 2- to 3-log reduction in viremia comparing to vehicle-treated controls. The overall survival percentage of ST-193-treated guinea pigs was 62.5% (10/16), compared with 0% in the ribavirin (0/8) and vehicle (0/7) groups [3].
|
| References |
|
| Molecular Formula |
C24H26CLN3O
|
|---|---|
| Molecular Weight |
407.935744762421
|
| Exact Mass |
407.176
|
| CAS # |
2320274-72-2
|
| Related CAS # |
ST-193;489416-12-8
|
| PubChem CID |
127020969
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.O(C)C1C=CC(=CC=1)N1C=NC2C=C(C=CC1=2)NCC1C=CC(=CC=1)C(C)C
|
| InChi Key |
YGSYVDRCHMVRDW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H25N3O.ClH/c1-17(2)19-6-4-18(5-7-19)15-25-20-8-13-24-23(14-20)26-16-27(24)21-9-11-22(28-3)12-10-21;/h4-14,16-17,25H,15H2,1-3H3;1H
|
| Chemical Name |
1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 150 mg/mL (~367.70 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4513 mL | 12.2567 mL | 24.5134 mL | |
| 5 mM | 0.4903 mL | 2.4513 mL | 4.9027 mL | |
| 10 mM | 0.2451 mL | 1.2257 mL | 2.4513 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
